Compare Biogen Inc (BIIB) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Innovative Industrial Properties Inc — how do they compare? Biogen Inc trades at $195.62 (market cap $28.34B), while Innovative Industrial Properties Inc trades at $63.7 (market cap $1.85B). The key difference: Biogen Inc is far larger — about 15.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | IIPR | |
|---|---|---|
Market Cap | $28.34B | $1.85B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $64.44 |
52-Week Low | $122.68 | $44.58 |
Enterprise Value | $30.62B | $2.23B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
IIPR trades at $63.78, down 1.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 but missing in Q1 2026, with revenue declining to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new debt, while cannabis rescheduling progress offers regulatory tailwinds.
The outlook for IIPR balances a high dividend yield and improved balance sheet against revenue declines and tenant risks. Investment opportunities include potential re-rating from regulatory changes and stable cash flows, but risks involve sector volatility and earnings inconsistency. Analyst sentiment is mixed with a Hold consensus, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
